34.12
-0.06 (-0.18%)
| Previous Close | 34.18 |
| Open | 33.90 |
| Volume | 57,183 |
| Avg. Volume (3M) | 112,353 |
| Market Cap | 319,645,024 |
| Price / Sales | 32.17 |
| Price / Book | 1.76 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Operating Margin (TTM) | -981.18% |
| Diluted EPS (TTM) | -9.42 |
| Total Debt/Equity (MRQ) | 32.52% |
| Current Ratio (MRQ) | 9.41 |
| Operating Cash Flow (TTM) | -62.63 M |
| Levered Free Cash Flow (TTM) | -61.34 M |
| Return on Assets (TTM) | -29.82% |
| Return on Equity (TTM) | -60.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Korro Bio, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.18% |
| % Held by Institutions | 104.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| 72 Investment Holdings, Llc | 30 Sep 2024 | 276,831 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 147.00 (Raymond James, 330.83%) | Buy |
| Median | 90.00 (163.78%) | |
| Low | 25.00 (Chardan Capital, -26.73%) | Buy |
| Average | 87.33 (155.95%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 18.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 13 Aug 2025 | 25.00 (-26.73%) | Buy | 18.93 |
| HC Wainwright & Co. | 13 Aug 2025 | 90.00 (163.77%) | Buy | 18.93 |
| 24 Jul 2025 | 100.00 (193.08%) | Buy | 15.90 | |
| Raymond James | 13 Aug 2025 | 147.00 (330.83%) | Buy | 18.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Aug 2025 | Announcement | Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates |
| 21 Jul 2025 | Announcement | Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |